LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Torin1 | 0.12 | uM | LJP6 | 3 | O17 | 72 | hr | 1476 | 1418 | 3694 | 0.3839 | -0.0265 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 1 | I23 | 72 | hr | 1476 | 1285 | 3694 | 0.3479 | -0.0865 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 2 | I23 | 72 | hr | 1476 | 1339 | 3694 | 0.3625 | -0.0621 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 3 | I23 | 72 | hr | 1476 | 1245 | 3694 | 0.3370 | -0.1045 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 1 | B17 | 72 | hr | 1476 | 1277 | 3694 | 0.3457 | -0.0901 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 2 | B17 | 72 | hr | 1476 | 1245 | 3694 | 0.3370 | -0.1045 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 3 | B17 | 72 | hr | 1476 | 1238 | 3694 | 0.3351 | -0.1077 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 1476 | 2786 | 3694 | 0.7542 | 0.5905 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 1476 | 2810 | 3694 | 0.7607 | 0.6013 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 1476 | 2737 | 3694 | 0.7409 | 0.5684 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 1 | M05 | 72 | hr | 1476 | 3603 | 3694 | 0.9754 | 0.9589 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 2 | M05 | 72 | hr | 1476 | 3627 | 3694 | 0.9819 | 0.9698 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 3 | M05 | 72 | hr | 1476 | 3974 | 3694 | 1.0758 | 1.1263 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 1 | C17 | 72 | hr | 1476 | 3811 | 3694 | 1.0317 | 1.0527 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 2 | C17 | 72 | hr | 1476 | 4021 | 3694 | 1.0885 | 1.1475 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 3 | C17 | 72 | hr | 1476 | 4089 | 3694 | 1.1069 | 1.1781 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 1 | G17 | 72 | hr | 1476 | 3406 | 3694 | 0.9220 | 0.8701 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 2 | G17 | 72 | hr | 1476 | 3118 | 3694 | 0.8441 | 0.7402 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 3 | G17 | 72 | hr | 1476 | 3821 | 3694 | 1.0344 | 1.0573 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 1 | G17 | 72 | hr | 1476 | 2929 | 3694 | 0.7929 | 0.6550 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 2 | G17 | 72 | hr | 1476 | 3111 | 3694 | 0.8422 | 0.7371 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 3 | G17 | 72 | hr | 1476 | 3500 | 3694 | 0.9475 | 0.9125 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 1 | L11 | 72 | hr | 1476 | 1393 | 3694 | 0.3771 | -0.0378 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 2 | L11 | 72 | hr | 1476 | 1741 | 3694 | 0.4713 | 0.1192 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 3 | L11 | 72 | hr | 1476 | 1556 | 3694 | 0.4212 | 0.0358 |